Activation of p38 Mitogen-Activated Protein Kinase Drives Dendritic Cells to Become Tolerogenic in Ret Transgenic Mice Spontaneously Developing Melanoma

Skin Cancer Unit, German Cancer Research Center and University Hospital Mannheim, Heidelberg, Germany.
Clinical Cancer Research (Impact Factor: 8.19). 07/2009; 15(13):4382-90. DOI: 10.1158/1078-0432.CCR-09-0399
Source: PubMed

ABSTRACT The purpose of the study was to investigate signaling molecules involved in the acquisition of tolerogenic properties by dendritic cells (DC) in ret transgenic mice with spontaneous melanoma progression and to target these molecules to overcome the barrier for effective melanoma immunotherapy.
DC functions and expression patterns of p38 mitogen-activated protein kinase (MAPK) in DCs were evaluated in a ret transgenic murine cutaneous melanoma model, which shows high similarity to human cutaneous melanoma with respect to clinical development. In contrast to transplantation melanoma models (like B16), this model allows the study of melanoma progression under conditions of natural interactions between tumor and host cells over time.
We showed a strong tumor infiltration with immature DCs and a reduction in the number of mature DCs in lymphoid organs during melanoma progression. DCs from melanoma-bearing mice secreted significantly more interleukin 10 and less interleukin 12p70, and showed a decreased capacity to activate T cells compared with DCs from tumor-free animals. Observed DC dysfunction was linked to considerable activation of p38 MAPK. Inhibition of its activity in spleen DCs from tumor-bearing mice led to normalization of their cytokine secretion pattern and T-cell stimulation capacity.
Our data show a critical role of constitutively activated p38 MAPK in the acquirement of tolerogenic pattern by DCs during melanoma progression that contributes to the suppression of antitumor T-cell immune responses. We suggest that new strategies of melanoma immunotherapy can include inhibitors of p38 MAPK activity in DCs.


Available from: Dirk Schadendorf, Apr 18, 2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Tumors are composed of heterogeneous cell populations recruited by cancer cells to promote growth and metastasis. Among cells comprising the tumor stroma, myeloid-derived cells play pleiotropic roles in supporting tumorigenesis at distinct stages of tumor development. The tumor-infiltrating myeloid cell contingent is composed of mast cells, neutrophils, dendritic cells, macrophages, and myeloid-derived suppressor cells. Such cells are capable of evading the hostile tumor environment typically prone to immune cell destruction and can even promote angiogenesis, chronic inflammation, and invasion. This paper briefly summarizes the different myeloid-derived subsets that promote tumor development and the strategies that have been used to counteract the protumorigenic activity of these cells. These strategies include myeloid cell depletion, reduction of recruitment, and inactivation or remodeling of cell phenotype. Combining drugs designed to target tumor myeloid cells with immunotherapies that effectively trigger antitumor adaptive immune responses holds great promise in the development of novel cancer treatments.
    OncoImmunology 04/2014; 3:e28398. DOI:10.4161/onci.28398 · 6.28 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Melanoma is known for its rapid progression, metastasis to distant organs and therapeutic resistance. Despite high melanoma immunogenicity, the results of immunotherapeutic clinical studies are mostly unsatisfactory. One explanation is the development of strong immunosuppression mediated by highly immunosuppressive regulatory leukocytes, in particular, myeloid-derived suppressor cells (MDSCs). These cells were found to be enriched and activated in the melanoma microenvironment, inducing a profound impairment of anti-tumor immune responses and leading to the tumor progression. Therefore, understanding the mechanisms of MDSC generation, migration to the tumor site and activation as well as their targeting is important for the development of novel strategies for effective melanoma immunotherapy. We suggest that such therapeutic approaches should involve the inhibition of MDSC-mediated immunosuppressive melanoma microenvironment combined with other immunologic treatments.
    Journal der Deutschen Dermatologischen Gesellschaft 09/2014; 12(11). DOI:10.1111/ddg.12411 · 1.40 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: ZusammenfassungMelanome sind bekannt für ihre schnelle Progression, Fernmetastasierung und Therapieresistenz. Trotz ihrer hohen Immunogenität sind die Ergebnisse immuntherapeutischer klinischer Studien bisher unbefriedigend geblieben. Eine Erklärung dafür ist die starke immunsupprimierende Wirkung sogenannter myeloider Suppressorzellen [myeloid-derived suppressor cells (MDSCs)], regulatorischen Leukozyten, die in der Mikroumgebung des Tumors angereichert und aktiviert werden, und dort durch eine starke Unterdrückung der Immunantwort die Tumorprogression erlauben.Daher ist das Verständnis der Mechanismen der MDSC-Bildung, ihrer Migration in die Tumorumgebung und ihrer Aktivierung essentiell für die Entwicklung neuer Strategien für eine effektive Immuntherapie bei Melanomen. Unserer Ansicht nach sollten derartige Therapieansätze eine Inhibition des immunsuppressiven Mikromilieus des Tumors mit anderen immunologischen Behandlungen kombinieren.
    Journal der Deutschen Dermatologischen Gesellschaft 11/2014; 12(11). DOI:10.1111/ddg.12411_suppl · 1.40 Impact Factor